Bob Bradway, Amgen CEO (Justin Kase Conder/AP Images for Amgen)
Amgen enlists TCR startup TScan to work on Crohn's in deal potentially worth $500M+
Amgen is taking a closer look at using T cells for inflammation, announcing a new deal Tuesday with TCR upstart TScan Therapeutics.
The companies will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
